Online assessment of ALS functional rating scale compares well to in-clinic evaluation: A prospective trial

Amyotrophic Lateral Sclerosis

Volumn 13, Issue 2, 2012, Pages 210-216

  Maier, André ^a   Holm, Teresa ^a   Wicks, Paul ^b   Steinfurth, Laura ^a   Linke, Peter ^a   Münch, Christoph ^a   Meyer, Robert ^b   Meyer, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Patientslikemecom Inc Research and Development   (United States)

Author keywords

ALS Functional Rating Scale; ALSFRS R; Amyotrophic lateral sclerosis; Online self assessment; Patient reported outcomes

Indexed keywords

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; ONLINE SYSTEM; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF EVALUATION; SELF REPORT; TIME PERCEPTION;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; AMYOTROPHIC LATERAL SCLEROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERNET; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; SELF-ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84856622261     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482968.2011.633268     Document Type: Article

References (33)

1. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurol. 1996; 53:141-7.
2. Voustianiouk A, Seidel G, Panchal J, Sivak M, Czaplinski A, Yen A, et al. ALSFRS and Appel ALS scores: discordance with disease progression. Muscle Nerve. 2008;37:668-72. (Pubitemid 351590560)
3. Wicks P, Massagli MP, Wolf C, Heywood J. Measuring function in advanced ALS: validation of ALSFRS-EX extension items. Eur J Neurol. 2009;16:353-9.
4. Cedarbaum JM, Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol Sci. 1997;152 (Suppl 1):S1-9. (Pubitemid 27505283)
5. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respira-tory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13-21. (Pubitemid 29502501)
6. Kaufmann P, Levy G, Montes J, Buchsbaum R, Barsdorf AI, Battista V, et al. Excellent inter-rater, intra-rater, and telephone- administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Lateral Scler. 2007;8:42-6. (Pubitemid 46322939)
7. Kasarskis EJ, Dempsey-Hall L, Thompson MM, Luu LC, Mendiondo M, Kryscio R. Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:50-4. (Pubitemid 40668248)
8. Miano B, Stoddard GJ, Davis S, Bromberg MB. Interevaluator reliability of the ALS functional rating scale. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:235-9. (Pubitemid 40125191)
9. Mannino M, Cellura E, Grimaldi G, Volanti P, Piccoli F, La Bella V. Telephone follow-up for patients with amyotrophic lateral sclerosis. Eur J Neurol. 2007;14:79-84. (Pubitemid 46088041)
10. Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, et al. A randomized, placebocontrolled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003;61:456-64. (Pubitemid 37025360)
11. Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53:437-45. (Pubitemid 36373255)
12. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology. 1996;46:1244-9.
13. Miller RG, Moore DH II, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 2001;56:843-8. (Pubitemid 32293584)
14. Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS progression. Journal of the Neurological Sciences. 2008;275:69-73.
15. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial Clinical limits of amyotrophic lateral sclerosis workshop contributors. Journal of the Neurological Sciences. 1994;124 (Suppl):96-107.
16. Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/ motor neuron disease: the ALSAQ-40. J Neurol. (Research Support, Non-U.S. Govt). 1999;246(Suppl 3):III16-21.
17. Wilson MM, Thomas DR, Rubenstein LZ, Chibnall JT, Anderson S, Baxi A, et al. Appetite assessment: simple appetite questionnaire predicts weight loss in communitydwelling adults and nursing home residents. Am J Clin Nutr. 2005;82:1074-81. (Pubitemid 43779767)
18. Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y. Development and validation of the cancer dyspnoea scale: a multidimensional, brief, self-rating scale. Br J Cancer. (Research Support, Non-U.S. Govt). 2000;82:800-5. (Pubitemid 30085229)
19. G B*. A category scale with ratio properties for intermodal and interindividual comparisons. In: Geissler, Hans-Georg, Petzold, Peter, editor. Psychophysical judgement and the process of perception. Berlin: VEB Deutscher Verlag der Wissenschaften; 1982. pp. 25-34.
20. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8:135-60. (Pubitemid 29425900)
21. Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006; 66:265-7. (Pubitemid 43970171)
22. Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, et al. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257:1713-7.
23. Montes J, Levy G, Albert S, Kaufmann P, Buchsbaum R, Gordon PH, et al. Development and evaluation of a selfadministered version of the ALSFRS-R. Neurology. (Randomized Controlled Trial Research Support, Non-U.S. Govt). 2006;67:1294-6. (Pubitemid 44563849)
24. Rose M, Bezjak A. Logistics of collecting patient-reported outcomes (PROs) in clinical practice: an overview and practical examples. Qual Life Res. 2009;18:125-36.
25. Gwaltney CJ, Shields AL, Shiffman S. Equivalence of electronic and paper-and-pencil administration of patientreported outcome measures: a meta-analytic review. Value in health. The Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2008;11: 322-33. (Pubitemid 351473608)
26. Bettinville A, Rabenberg H, Hansgen KD. An enquiry into the WILDE Intelligence Test (WIT): comparability of application of the paper-pencil version vs. the computer based application: an analysis based on data of the Leipzig Vocational Retraining Centre. Rehabilitation (Stuttg). 2005;44: 237-43. (Pubitemid 41191988)
27. Bliven BD, Kaufman SE, Spertus JA. Electronic collection of health-related quality of life data: validity, time benefits, and patient preference. Qual Life Res. 2001;10:15-22.
28. Ryan JM, Corry JR, Attewell R, Smithson MJ. A comparison of an electronic version of the SF-36 General Health Questionnaire to the standard paper version. Qual Life Res. 2002;11:19-26. (Pubitemid 34293383)
29. Wicks P, Vaughan TE, Massagli MP, Heywood J. Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Nat Biotechnol. 2011;29:411-4.
30. Doward LC, Gnanasakthy A, Baker MG. Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcomes. 2010;8:89.
31. Abernethy AP, Wheeler JL, Zafar SY. Management of gastrointestinal symptoms in advanced cancer patients: the rapid learning cancer clinic model. Curr Opin Support Palliat Care. 2010;4:36-45.
32. U.S. Department of Health and Human Services Food and Drug Administration, FDA. Guidance for Industry: Patient- Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. Available from: www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM193282.pdf
33. Wicks P, Massagli M, Frost J, Brownstein C, Okun S, Vaughan T, et al. Sharing health data for better outcomes on PatientsLikeMe. J Med Internet Res. 2010;12:19.